Division of Endocrinology and Metabolism, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.
Thyroid. 2011 Nov;21(11):1191-8. doi: 10.1089/thy.2011.0146. Epub 2011 Oct 18.
Fine needle aspiration (FNA), although very reliable for cytologically benign and malignant thyroid nodules, has much lower predictive value in the case of suspicious or indeterminate nodules. We aimed to identify clinical predictors of malignancy in the subset of patients with suspicious FNA cytology.
We reviewed the electronic medical records of 462 patients who had FNA of thyroid nodules at our institution with a suspicious cytological diagnosis, and underwent surgery at Mayo Clinic between January 2004 and September 2008. Demographic data including age, gender, history of exposure to radiation and use of thyroid hormone was collected. The presence of single versus multiple nodules by ultrasonography, nodule size, and serum thyroid-stimulating harmone (TSH) level before thyroid surgery were recorded. Analysis of the latter was limited to patients not taking thyroid hormone or antithyroid drugs at the time of FNA.
Of the 462 patients, 327 had lesions suspicious for follicular neoplasm (S-FN) or Hürthle cell neoplasm (S-HCN), 125 had cytology suspicious for papillary carcinoma (S-PC) and 10 had a variety of other suspicious lesions (medullary cancer, lymphoma and atypical). Malignancy rate for suspicious neoplastic lesions (FN+HCN) was ∼15%, whereas malignancy rate for lesions S-PC was 77%. Neither age, serum TSH level, or history of radiation exposure were associated with increased malignancy risk. The presence of multiple nodules (41.1% vs. 26.4%, p=0.0014) or smaller nodule size (2.6±1.8 cm vs. 2.9±1.6 cm, p=0.008) was associated with higher malignancy risk. In patients with cytology suspicious for neoplasm (FN, HCN) malignancy risk was higher in those receiving thyroid hormone therapy than in nonthyroid hormone users (37.7% vs. 16.5%, p=0.0004; odds ratio: 3.1), although serum TSH values did not differ significantly between thyroid hormone users and nonusers.
In patients with cytologically suspicious thyroid nodules, the presence of multiple nodules or smaller nodule size was associated with increased risk of malignancy. In addition, our study demonstrates for the first time, an increased risk of malignancy in patients with nodules suspicious for neoplasm who are taking thyroid hormone therapy. The reason for this association is unknown.
细针穿刺(FNA)对于细胞学良性和恶性甲状腺结节非常可靠,但对于可疑或不确定的结节,其预测价值要低得多。我们旨在确定可疑 FNA 细胞学患者亚组中恶性肿瘤的临床预测因子。
我们回顾了 2004 年 1 月至 2008 年 9 月在我们机构接受甲状腺结节 FNA 检查且细胞学诊断可疑,并在梅奥诊所接受手术的 462 名患者的电子病历。收集了年龄、性别、辐射暴露史和甲状腺激素使用史等人口统计学数据。超声检查显示单个或多个结节、结节大小以及甲状腺手术前血清促甲状腺激素(TSH)水平。对后者的分析仅限于在 FNA 时未服用甲状腺激素或抗甲状腺药物的患者。
在 462 名患者中,327 名患者的病变可疑为滤泡性肿瘤(S-FN)或 Hurthle 细胞肿瘤(S-HCN),125 名患者的细胞学可疑为乳头状癌(S-PC),10 名患者的病变可疑为其他各种病变(髓样癌、淋巴瘤和非典型)。可疑肿瘤性病变(FN+HCN)的恶性率约为 15%,而 S-PC 病变的恶性率为 77%。年龄、血清 TSH 水平或辐射暴露史均与恶性风险增加无关。多发性结节(41.1% vs. 26.4%,p=0.0014)或较小的结节大小(2.6±1.8cm vs. 2.9±1.6cm,p=0.008)与更高的恶性风险相关。在细胞学可疑为肿瘤(FN、HCN)的患者中,接受甲状腺激素治疗的患者恶性风险高于未接受甲状腺激素治疗的患者(37.7% vs. 16.5%,p=0.0004;优势比:3.1),尽管甲状腺激素使用者和非使用者的血清 TSH 值无显著差异。
在细胞学可疑的甲状腺结节患者中,多发性结节或较小的结节大小与恶性风险增加相关。此外,我们的研究首次表明,接受甲状腺激素治疗的可疑肿瘤结节患者恶性风险增加。这种关联的原因尚不清楚。